$375.41
1.83% today
Nasdaq, Nov 26, 01:07 pm CET
ISIN
US91307C1027
Symbol
UTHR

United Therapeutics Corporation Target price 2024 - Analyst rating & recommendation

United Therapeutics Corporation Classifications & Recommendation:

Buy
53%
Hold
35%
Sell
12%

United Therapeutics Corporation Price Target

Target Price $395.83
Price $368.66
Potential
Number of Estimates 12
12 Analysts have issued a price target United Therapeutics Corporation 2025 . The average United Therapeutics Corporation target price is $395.83. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 9 Analysts recommend United Therapeutics Corporation to buy, 6 to hold and 2 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the United Therapeutics Corporation stock has an average upside potential 2025 of . Most analysts recommend the United Therapeutics Corporation stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Billion $ 2.33 2.88
20.20% 23.67%
EBITDA Margin 53.35% 52.89%
0.88% 0.86%
Net Margin 37.98% 38.35%
9.87% 0.98%

13 Analysts have issued a sales forecast United Therapeutics Corporation 2024 . The average United Therapeutics Corporation sales estimate is

$2.9b
Unlock
. This is
4.43% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$2.9b 6.67%
Unlock
, the lowest is
$2.8b 2.58%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $2.3b 20.20%
2024
$2.9b 23.67%
Unlock
2025
$3.2b 10.59%
Unlock
2026
$3.4b 6.28%
Unlock
2027
$3.9b 14.32%
Unlock
2028
$4.1b 6.18%
Unlock

5 Analysts have issued an United Therapeutics Corporation EBITDA forecast 2024. The average United Therapeutics Corporation EBITDA estimate is

$1.5b
Unlock
. This is
13.12% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$1.7b 24.47%
Unlock
, the lowest is
$1.4b 5.73%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $1.2b 19.14%
2024
$1.5b 22.61%
Unlock
2025
$1.7b 10.56%
Unlock
2026
$1.7b 1.86%
Unlock
2027
$2.7b 55.46%
Unlock
2028
$3.4b 26.55%
Unlock

EBITDA Margin

2023 53.35% 0.88%
2024
52.89% 0.86%
Unlock
2025
52.88% 0.02%
Unlock
2026
50.68% 4.16%
Unlock
2027
68.92% 35.99%
Unlock
2028
82.13% 19.17%
Unlock

10 United Therapeutics Corporation Analysts have issued a net profit forecast 2024. The average United Therapeutics Corporation net profit estimate is

$1.1b
Unlock
. This is
8.65% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$1.2b 14.01%
Unlock
, the lowest is
$1.0b 2.94%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $884m 32.07%
2024
$1.1b 24.89%
Unlock
2025
$1.3b 15.29%
Unlock
2026
$1.3b 2.75%
Unlock
2027
$1.6b 21.11%
Unlock
2028
$1.7b 9.45%
Unlock

Net Margin

2023 37.98% 9.87%
2024
38.35% 0.98%
Unlock
2025
39.98% 4.25%
Unlock
2026
38.65% 3.33%
Unlock
2027
40.95% 5.95%
Unlock
2028
42.21% 3.08%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ 19.81 24.74
32.07% 24.89%
P/E 14.90
EV/Sales 4.70

10 Analysts have issued a United Therapeutics Corporation forecast for earnings per share. The average United Therapeutics Corporation <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$24.74
Unlock
. This is
8.65% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$25.96 14.01%
Unlock
, the lowest is
$23.44 2.94%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $19.81 32.07%
2024
$24.74 24.89%
Unlock
2025
$28.52 15.28%
Unlock
2026
$29.31 2.77%
Unlock
2027
$35.50 21.12%
Unlock
2028
$38.85 9.44%
Unlock

P/E ratio

Current 16.19 27.18%
2024
14.90 7.97%
Unlock
2025
12.92 13.29%
Unlock
2026
12.58 2.63%
Unlock
2027
10.39 17.41%
Unlock
2028
9.49 8.66%
Unlock

Based on analysts' sales estimates for 2024, the United Therapeutics Corporation stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.91 23.06%
2024
4.70 4.25%
Unlock
2025
4.25 9.58%
Unlock
2026
4.00 5.91%
Unlock
2027
3.50 12.52%
Unlock
2028
3.30 5.82%
Unlock

P/S ratio

Current 5.97 21.19%
2024
5.72 4.25%
Unlock
2025
5.17 9.58%
Unlock
2026
4.86 5.91%
Unlock
2027
4.26 12.52%
Unlock
2028
4.01 5.82%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today